PO45 Clinicopathological evaluation and outcome of young breast cancer patients developing brain metastasis in single institution cohort von Tuxen, M

Volltext

CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use von DUFFY, M.J., BONFRER, J.M., KULPA, J., RUSTIN, G.J.S., SOLETORMOS, G., TORRE, G.C., TUXEN, M.K., ZWIRNER, M.

Volltext

A randomised study of tailored toxicity-based dosage of fluorouracil-epirubicin-cyclophosphamide chemotherapy for early breast cancer (SBG 2000-1) von Lindman, H., Andersson, M., Ahlgren, J., Balslev, E., Sverrisdottir, A., Holmberg, S.B., Bengtsson, N.O., Jacobsen, E.H., Jensen, A.B., Hansen, J., Tuxen, M.K., Malmberg, L., Villman, K., Anderson, H., Ejlertsen, B., Bergh, J., Blomqvist, C.

Volltext

Exploratory Phase III Study of Paclitaxel and Cisplatin Versus Paclitaxel and Carboplatin in Advanced Ovarian Cancer von NEIJT, J. P, ENGELHOLM, S. A, TUXEN, M. K, SØRENSEN, P. G, HANSEN, M, SESSA, C, DE SWART, C. A. M, HIRSCH, F. R, LUND, B, VAN HOUWELINGEN, H. C

Volltext

Defining progression of ovarian carcinoma during follow-up according to CA 125: A North Thames Ovary Group study von Rustin, G. J. S., Nelstrop, A. E., Tuxen, M. K., Lambert, H. E.

Volltext

Serum tumour marker CA 125 in monitoring of ovarian cancer during first-line chemotherapy von Tuxen, M K, Sölétormos, G, Dombernowsky, P

Volltext

197P Current treatment landscape of HR+/HER2- advanced breast cancer in the Nordics: A modified Delphi study von Karihtala, P., Valachis, A., Tuxen, M., Geisler, J.

Volltext

Current treatment landscape of HR+/HER2-advanced breast cancer in the Nordics: A modified Delphi study von Karihtala, P., Valachis, A, Tuxen, M., Geisler, J.

Volltext

Network Address Translation for the Stream Control Transmission Protocol von Tuxen, M., Rungeler, I., Stewart, R., Rathgeb, E.

Volltext

Advanced epithelial ovarian cancer : 1998 consensus statements von BEREK, J. S, BERTELSEN, K, HARPER, P. G, HORVATH, G, KAYE, S. B, LÜCK, H. J, LUND, B, MCGUIRE, W. P, NEIJT, J. P, OZOLS, R. F, PARMAR, M. K. B, PICCART-GEBHART, M. J, DU BOIS, A, VAN RIJSWIJK, R, ROSENBERG, P, RUSTIN, G. J. S, SESSA, C, THIGPEN, J. T, TROPE, C, TUXEN, M. K, VERGOTE, I, VERMORKEN, J. B, WILLEMSE, P. H. B, BRADY, M. F, CARMICHAEL, J, EISENHAUER, E. A, GORE, M, GRENMAN, S, HAMILTON, T. C, HANSEN, S. W

Volltext

P334 Patient seminar for women operated for breast cancer von Frydensberg, M, Gessoe, L, Tuxen, M

Volltext

Tumor markers in the management of patients with ovarian cancer von Tuxen, Malgorzata K., Sölétormos, György, Dombernowsky, Per

Volltext

Neurotoxicity secondary to antineoplastic drugs von Tuxen, Malgorzata K., Hansen, Steen Werner

Volltext

Serum tumor marker CA 125 for monitoring ovarian cancer during follow-up von Tuxen, M. K., SöLétormos, G., Dombernowsky, P.

Volltext

Assessment of Biological Variation and Analytical Imprecision of CA 125, CEA, and TPA in Relation to Monitoring of Ovarian Cancer von Tuxen, Malgorzata K., Sölétormos, György, Petersen, Per Hyltoft, Schiøler, Vibeke, Dombernowsky, Per

Volltext

The role of second-look laparotomy in the long-term survival in ovarian cancer von TUXEN, M. K, STRAUSS, G, LUND, B, HANSEN, M

Volltext

Gemcitabine in the treatment of ovarian cancer von HANSEN, S. W, TUXEN, M. K, SESSA, C

Volltext

Interpretation of Sequential Measurements of Cancer Antigen 125 (CA 125), Carcinoembryonic Antigen (CEA) and Tissue Polypeptide Antigen (TPA) Based on Analytical Imprecision and Bi... von Tuxen, Malgorzata K., Sölétormos, György, Petersen, Per Hyltoft, Dombernowsky, Per

Volltext

Biological variation and analytical imprecision of CA 125 in patients with ovarian cancer von Tuxen, M. K., Rustin, G. J. S., Dombernowsky, P., Sölétormos, G., Nelstrop, A. E.

Volltext

Evaluation of Concurrent Multipath Transfer over Dissimilar Paths von Adhari, H, Dreibholz, T, Becke, M, Rathgeb, E P, Tüxen, M

Volltext bestellen